1. McMillan CW, Webster WP, Roberts HR, Blythe WB. Continuous intravenous infusion of factor viii in classic haemophilia. Br J Haematol. 1970;18:659-667.
2.
2. Hathaway WE, Christian MJ, Clarke SL, Hasiba U. Comparison of continuous and intermittent factor VIII concentrate therapy in hemophilia A. Am J Hematol. 1984;17:85-88.
3.
3. Weinstein RE, Bona RD, Rickles FR. Continuous infusion of Monoclonal Antibody-Purified Factor VIII. Am J Hematol. 1991;36:211-221.
4.
4. Schulman S, Varon D, Keller N, et al. Monoclonal Purified F VIII for continuous infusion: stability, microbiological safety and clinical experience. Thromb Haemost. 1994;72:403-407.
5.
5. Bona RD, Weinstein RE, Weisman SJ, et al. The use of continuous infusion of factor concentrates in the treatment of hemophilia.Am J Hematol. 1989;32:8-13.
6.
6. Gordon EM, Mungo R, Goldsmith JC. Lingual hemorrhage in a patient with hemophilia A complicated by a high titer inhibitor. AmJ Ped Hematol Oncol. 1993;15:107-110.
7.
7. Gordon EM, Al-Batniji F, Goldsmith JC.Continuous infusion of monoclonal antibody-purified factor VIII: rational approach to serious hemorrhage in patients with allo-/autoantibodies to factor VIII. Am J Hematol. 1994;45:142-145.
8.
8. Gordon EM, Month S, Goldsmith JC. Immune tolerance induction by continuous infusion of monoclonal antibody-purified (MOAB) factor VIII in children. Blood. 1993;82:62a-62a.
9.
9. Nilsson IM, Kirkwood TBL, Barrowcliffe TW. In vivo recovery of factor VIII: a comparison of one-stage and two-stage assay methods. Thromb Haemost. 1979;42:1230-1239.
10.
10. Kasper CK, Aledort LM, Counts, RB. A more uniform measurement of factor VIII inhibitors. Throm Diath Haemorrh. 1975;34:875-876.